Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$140.80 USD
+3.76 (2.74%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $140.63 -0.17 (-0.12%) 7:00 PM ET
4-Sell of 5 4
F Value C Growth B Momentum F VGM
Brokerage Reports
Ascendis Pharma A/S [ASND/]
Reports for Purchase
Showing records 201 - 220 ( 303 total )
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
TransCon CNP/Achondroplasia Presentations At ISDS.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
2019 PacGrow Healthcare Conference: Day 1 Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
R-D Day Reinforces Superiority of TC-hGH/GHD; Selloff Overdone In Our View
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
CORRECTION: Q1 Financials: Strong Cash Position; Next: R-D Day
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Preliminary fliGHt Data Highlights TransCon hGH''s Favorable Safety Profile
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Upcoming Presentations for TransCon hGH and TransCon PTH
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Q4/FY18: Strong Cash Position; Next: TC-hGH Phase 3 heiGHt Data at PES/PAS
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Q2 fliGHt Data Likely Less Material Than We Thought; Focus on TC-PTH Ph2 in Q4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
TC-hGH and TC-PTH Program Updates; Ph 3 fliGHt Data in Q2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L